Beijing Chemclin Biotech Completes Private Placement Of $16.5 Million
This article was originally published in PharmAsia News
Executive Summary
Beijing Chemclin Biotech, China's leading in vitro diagnostic reagents and instruments maker, has completed its second round of private placement totalling $16.5 million. The funding is led by China Healthcare Partnership, with participation of first round investors WI Harper Group, Siemens Venture Capital and SB China Venture Capital. Against a background of economic recession, Chemclin's fundraising success shows that investors have confidence in China as well as in the company's development, technology and internationalized management system. Chemclin will next focus on market channel broadening, products development and talent build-up. (Click here for more - Chinese Language)